The approval covers Imfinzi as neoadjuvant treatment before surgery and as adjuvant monotherapy afterward. It is based on results from the Phase 3 Volga trial.

Patients who received the regimen had a 49% lower risk of disease progression or recurrence, according to the trial results. On the key secondary endpoint of overall survival, the combination reduced the risk of death by 42% compared with the comparison arm.